Cleft lip with or without cleft palate (CL/P) is one of the most frequent human congenital defects. Treatments for this condition are possible but can only partially rescue related speech and structural alterations, and require lifelong medical management. To find new treatments it is important to further understand the mechanisms of clefting development. A current view is that alterations in facial shape or fusion of facial prominences – the tissues that give rise to orofacial structures – might play a role. However, available mouse models can only partially recapitulate clefting phenotypes. Here, Trevor Williams and colleagues develop a new mouse model that bears mutations in the gene encoding transcription factor AP-2α (Tfap2a) – associated with human CL/P – and that shows full CL/P penetrance. By employing geometric morphometrics, the authors analysed facial growth and shape changes in control and mutant mice and found that, in mutants, clefting develops owing to altered facial morphology. Interestingly, mutants also exhibited a slight increase in fibroblast growth factor 8 (Fgf8) expression; decreasing Fgf8 dosage in these mice could partially rescue CL/P. The study suggests that orofacial development is particularly sensitive to small changes in gene expression and that FGF signalling could be targeted as an early therapeutic intervention in CL/P. Page 31
Insights into orofacial birth defects
Insights into orofacial birth defects. Dis Model Mech 1 January 2015; 8 (1): e0101. doi:
Download citation file:
Advertisement
Cited by
Interviews with Biologists @ 100 conference speakers

Explore our interviews with keynote speakers from the Biologists @ 100 conference, hosted to celebrate our publisher’s 100th anniversary, where we discuss climate change and biodiversity with Hans-Otto Pörtner and Jane Francis, health and disease with Charles Swanton and emerging technologies with Manu Prakash and Jennifer Lippincott-Schwartz.
A new perspective on disease research
DMM publishes perspectives – peer-reviewed articles that provide expert analysis of a topic important to the disease research community. Read our collection from authors presenting new or potentially controversial ideas or hypotheses, to help address future challenges and forge new directions.
Read & Publish Open Access publishing: what authors say

We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Fast & Fair peer review

Our sister journal Biology Open has recently launched the next phase of their Fast & Fair peer review initiative: offering high-quality peer review within 7 working days. To learn more about BiO’s progress and future plans, read the Editorial by Daniel Gorelick, or visit the Fast & Fair peer review page.
History of our journals

As our publisher, The Company of Biologists, turns 100 years old, read about DMM’s history and explore the journey of each of our sister journals: Development, Journal of Cell Science, Journal of Experimental Biology and Biology Open.
Other journals from
The Company of Biologists